当科における薬剤関連顎骨壊死（MRONJ）の臨床的検討

1 2014 2018 MRONJ BP Dmab 2003 Marx1 BP BP Dmab medication - related osteonecrosis of the jaws MRONJ systematic review2 ,3 ,4 MRONJ MRONJ 2014 4 2018 4 4 MRONJ 60 MRONJ 42 17 22 2020 MRONJ A Retrospective Clinical Evaluation of medication - related osteonecrosis of the jaw in our department Taniguchi Hiroki, Yamamoto Rina, Komatsu Kyosuke, Tida TadashiNakano Shintaro, Yada Mitsue, Yamada Ryuhei, Ishihara OsamuAbstract The purpose of this retrospective study is to evaluate the onset, risk factors.

2 And treatment of medication - related osteonecrosis of the jaw MRONJ . The subjects were 60 patients 8 males and 52 females, mean age: years who diagnosed as MRONJ between 2014 and 2018. The surgical treatment group showed improvements in symptoms in of the cases, while the conservative treatment group showed improvements in of the cases. This research suggests that surgical treatment is useful in treatment of words MRONJ, surgical treatment, conservative treatment18 stage 5 MRONJ stage 8 52 1 41 19 10 7 1 1 28 29 3 MRONJ MRONJ MRONJ 16 42 2 3 BP 34 BP 6 Dmab 17 36 42

3 12 24 10 24 36 2 12 1 19 stage MRONJ stage stage1 8 stage2 41 stage3 11 stage2 stage1 2 1 stage2 5 4 1 stage2 17 2 4 9 6 3 2 stage3 1 23 21 2 stage3 4 2 2 7 6 1 stage3 5 1 4 3 MRONJ stage 1 3 X 9 7 4 2003 Marx BP BP RANKL BRONJ 6 ARONJ antiresorptive agent- related osteonecrosis of the jaw 4 AAOMS MRONJ 7 BP Dmab

4 Stage1 Stage3 Stgage2 stage18 2 1 1 stage2 5 4 stage311 4 7 0 2 2 6 1 2 stage241 17 2 4 9 6 3 24 Stage3 2 21 2 1 2 20 MRONJ BP 10 69 0 90 10 0 8 MRONJ 1 MRONJ A: A:75 6 B X B 5 C 9 C 48 5 MRONJ AAOMS 2014 MRONJ 8 3 21 MRONJ 60 42 8 MRONJ MRONJ

5 800 1011 1012 MRONJ AAOMS MRONJ QOL stage2 MRONJ 9 MRONJ MRONJ 10 Stage3 MRONJ QOL 11 4 3 MRONJ MRONJ MRONJ 12 1 Marx RE.

6 Pamidronate Aredia and zole-dronate Zometa induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117, 20032 Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, Lenarda RD, Biasotto M:A systematic review of therapeutical approaches in bisphosphonates- related osteonecrosis of the jaw BRONJ . Oral Oncol 50: 1049-1057, Fliefel R, Tr ltzsch M, Kuehnisch J, Ehrenfeld M, Otto S: Treatment strategies and outcome of bisphosphonate- related osteonecrosis of the jaw BRONJ with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 44:568-585, Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S:Diagnosis and manage-ment of osteonecrosis of the jaw: a systematic review and international consensus.

7 J Bone Miner Res 30: 3-23, : 63 645-652 Qi WX, Tang LN, He AN, Yao Y, Shen Z : Risk of osteonecrosis of the jaw in cancer patients receiving denosumab:a me-ta-analysis of seven randomized controlled trials. Int J Clin Oncol 19:403-410, Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O Ryan F:American Association of Oral and Maxillofacial Surgeons position paper on medication - related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 72:1938-1956, : : 2016. https://www. jsoms. or. jp/medical/wp-content/uploads/2015/08/ 229 : medication - related osteonecrosis of the jaw MRONJ 62: 11-17 Taguchi A, Shiraki M, Tsukiyama T, Miyazaki T, Soen S, Nakamura T, Orimo H: Impact of osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis A-TOP Research Group.

8 Calcif Tissue Int. 97:542-550, 2015 11 : 41 77-84 2016 12 : ARONJ 153 22-27 2019